These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23026230)

  • 21. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contrast-enhanced ultrasound improves real-time imaging of ablation region during radiofrequency ablation: preliminary results.
    Wiggermann P; Zuber-Jerger I; Zausig Y; Loss M; Scherer MN; Schreyer AG; Stroszczynski C; Jung EM
    Clin Hemorheol Microcirc; 2011; 49(1-4):43-54. PubMed ID: 22214677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiofrequency ablation of subcapsular hepatocellular carcinoma: single center experience.
    Filippousis P; Sotiropoulou E; Manataki A; Konstantinopoulos O; Thanos L
    Eur J Radiol; 2011 Feb; 77(2):299-304. PubMed ID: 19733023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence.
    Murakami T; Ishimaru H; Sakamoto I; Uetani M; Matsuoka Y; Daikoku M; Honda S; Koshiishi T; Fujimoto T
    Cardiovasc Intervent Radiol; 2007; 30(4):696-704. PubMed ID: 17497071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.
    Waki K; Aikata H; Katamura Y; Kawaoka T; Takaki S; Hiramatsu A; Takahashi S; Toyota N; Ito K; Chayama K
    J Gastroenterol Hepatol; 2010 Mar; 25(3):597-604. PubMed ID: 20074153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The validity of radiofrequency ablation for hepatocellular carcinoma].
    Yokoyama Y; Yamasaki T; Kurokawa F; Okita K
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2105-9. PubMed ID: 15628752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography.
    Shiozawa K; Watanabe M; Takayama R; Takahashi M; Wakui N; Iida K; Sumino Y
    J Clin Ultrasound; 2010 May; 38(4):182-9. PubMed ID: 20232404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of microvascularization of liver tumor lesions with high resolution linear ultrasound and contrast enhanced ultrasound (CEUS) during surgery: First results.
    Jung EM; Ross CJ; Rennert J; Scherer MN; Farkas S; von Breitenbuch P; Schnitzbauer AA; Piso P; Lamby P; Menzel C; Schreyer AG; Feuerbach S; Schlitt HJ; Loss M
    Clin Hemorheol Microcirc; 2010; 46(2-3):89-99. PubMed ID: 21135485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of contrast-enhanced ultrasonography in selecting indication of radiofrequency ablation among hepatocellular carcinoma patients].
    Chen MH; Wu W; Yang W; Gao W; Dai Y; Yin SS; Huo L; Yan K
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3491-4. PubMed ID: 16686066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT.
    Park Y; Choi D; Lim HK; Rhim H; Kim YS; Kim SH; Lee WJ
    AJR Am J Roentgenol; 2008 Jul; 191(1):215-20. PubMed ID: 18562748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contrast-enhanced ultrasound-guided microwave ablation for hepatocellular carcinoma inconspicuous on conventional ultrasound.
    Liu F; Yu X; Liang P; Cheng Z; Han Z; Dong B
    Int J Hyperthermia; 2011; 27(6):555-62. PubMed ID: 21797695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT.
    Inoue T; Kudo M; Hatanaka K; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Ueshima K; Nishida N
    Oncology; 2013; 84 Suppl 1():51-7. PubMed ID: 23428859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT.
    Salvaggio G; Campisi A; Lo Greco V; Cannella I; Meloni MF; Caruso G
    Abdom Imaging; 2010 Aug; 35(4):447-53. PubMed ID: 19562414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma?
    Ricci P; Cantisani V; Drudi F; Pagliara E; Bezzi M; Meloni F; Calliada F; Erturk SM; D'Andrea V; D'Ambrosio U; Passariello R
    Ultraschall Med; 2009 Jun; 30(3):252-8. PubMed ID: 19280552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation.
    Kisaka Y; Hirooka M; Kumagi T; Uehara T; Hiasa Y; Kumano S; Tanaka H; Michitaka K; Horiike N; Mochizuki T; Onji M
    Liver Int; 2006 Dec; 26(10):1241-7. PubMed ID: 17105590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach.
    Kim HO; Kim SK; Son BH; Yoo CH; Hong HP; Cho YK; Kim BI
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):591-6. PubMed ID: 20007075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound.
    Bartolotta TV; Taibbi A; Midiri M; De Maria M
    Abdom Imaging; 2008; 33(5):501-11. PubMed ID: 17786507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous ultrasonography-guided radiofrequency ablation of hepatocellular carcinomas: usefulness of image fusion with three-dimensional ultrasonography.
    Park HJ; Lee MW; Rhim H; Cha DI; Kang TW; Lim S; Song KD; Lim HK
    Clin Radiol; 2015 Apr; 70(4):387-94. PubMed ID: 25582889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.